Merbarone, a catalytic inhibitor of DNA topoisomerase II, induces apoptosis in CEM cells through activation of ICE/CED-3-like protease

Molecular Pharmacology

Volumn 55, Issue 3, 1999, Pages 548-556

  Khélifa, Tayeb ^a   Beck, William T ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); MERBARONE; PROTEINASE;

APOPTOSIS; ARTICLE; CATALYSIS; CELL DEATH; COMPLEX FORMATION; DNA CLEAVAGE; EFFECTOR CELL; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SPECIFICITY; GENE INDUCTION; HUMAN; HUMAN CELL; MOLECULAR CLONING; PRIORITY JOURNAL; TRANSACTIVATION;

APOPTOSIS; ASPARAGINE; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CAENORHABDITIS ELEGANS PROTEINS; CASPASE 3; CASPASES; CYSTEINE ENDOPEPTIDASES; DNA TOPOISOMERASES, TYPE II; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION; GENES, JUN; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOGEN-ACTIVATED PROTEIN KINASE 9; MITOGEN-ACTIVATED PROTEIN KINASES; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASES; SIGNAL TRANSDUCTION; THIOBARBITURATES; TUMOR CELLS, CULTURED;

EID: 18744427475     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Boritzki TJ, Wolfard TS, Besser JA, Jackson RC and Fry DW (1988) Inhibition of type II topoisomerase by fostriecin. Biochem Pharmacol 37:4063-4068.
2. Chen M and Beck WT (1993) Teniposide-resistant CEM cells, which express mutant topoisomerase IIa, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res 53:5946-5953.
3. Chen M and Beck WT (1995) Differences in inhibition of chromosome separation and G2 arrest bv DNA topoisomerase II inhibitors merbarone and VM-26. Cancer Res 55:1509-1516.
4. Chen Y-R, Wang X, Templeton D, Davis RJ and Tan T-H (1996) The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J Biol Chem 271:31929-31936.
5. Chin YE, Kitagawa M, Kuida K, Flavell RA and Fu XY (1997) Activation of STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol 17:5328-5337.
6. Chomezynski P and Sacchi N (1987) Single-step method of RNA isolation by acid guanidine thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159.
7. Cohen GM (1997) Caspases: The executioners of apoptosis. Biochem J 326:1-16.
8. Colotta F, Polentarutti N, Sironi M and Mantovani A (1992) Expression and involvement of c-fos and c-jun protooncogenes in programmed cell death induced by growth factor deprivation in lymphoid cell lines. J Biol Chem 267:18278-18283.
9. Cooney DA, Covey JM, Kay GJ, Dalal M, McMahon JB and Johns DG (1985) Initial mechanistic studies with merbarone. Biochem Pharmacol 34:3395-3398.
10. Davis RJ (1994) MAP kinases: New JNK expands the group. Trends Biochem Sci 19:470-473.
11. Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Derijard B and Davis RJ (1996) Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 15:2760-2770.
12. Haga N, Naito M, Seimiya H, Tomida A, Dong J and Tsuruo T (1998) 2-deoxyglucose inhibits chemotherapeutic drug-induced apoptosis in human monocytic leukemia U937 cells with inhibition of c-Jun N-terminal kinase 1/stress-activated protein kinase activation. Int J Cancer 76:86-90.
13. Ham J, Babij C, Whitfield J, Pfarr CM, Lallemand D, Yaniv Y and Rubin LL (1995) A c-jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron 14:927-939.
14. Humke EW, Ni J and Dixit VM (1998) ERICE, a novel FLICE-activatable caspase. J Biol Chem 273:15702-15707.
15. Ishida R, Miki T, Narita T, Yui R, Sato M, Utsumi KR, Tanabe K and Andoh T (1991) Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: Mode of cell growth inhibition distinct from that of cleavable complex-forming type of inhibitors. Cancer Res 51:4909-4916.
16. Jensen PB, Sorensen BS, Schested M, Demant EJ, Kjeldsen E, Friche E and Hansen HH (1993) Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA cleavage and for overcoming topoisomerase II-related drug resistance. Biochem Pharmacol 45:2025-2035.
17. Karin M, Liu ZG and Zandi E (1997) AP-1 function and regulation. Curr Opin Cell Biol 9:240-246.
18. Kim R and Beck WT (1994) Differences between drug-sensitive and resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26. Cancer Res 54:4958-4966.
19. Kuida K, Zheng TS, Songqing N, Kuan C, Yang D, Karasuyama H, Rakic P and Flavell RA (1996) Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature (London) 384:368-372.
20. Kusumoto H, Rodgers QE, Boege F, Raimondi SC and Beck WT (1996) Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II. Cancer Res 56:2573-2583.
21. Lenczowski JM, Lourdes D, Eder AM, King LB, Zacharchuk CM and Ashwell JD (1997) Lack of a role for Jun kinase and AP-1 in Fas-induced apoptosis. Mol Cell Biol 17:170-181.
22. Lin A, Minden A, Martinetto H, Claret F-X, Lange-Carter C, Mercurio F, Johnson GL and Karin M (1995) Identification of a dual specificity kinase that activates Jun kinases and p38-Mpk2. Science 268:286-290.
23. Liu Z-G, Hsu H, Goeddel DV and Karin M (1996) Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappa B activation prevents cell death. Cell 87:565-576.
24. Mashima T, Naito M, Kataoka S, Kawai H and Tsuruo T (1995) Aspartate-based inhibition of interleukin-1b converting enzyme prevents antitumor agent-induced apoptosis in human myeloid leukemia U937 cells. Biochem Biophys Res Commun 209:907-915.
25. Mo Y-Y and Beck WT (1999) DNA damage signals induction of Fas ligand in tumor cells. Mol Pharmacol 55:216-222.
26. Nicholson DW, All A, Thornberry AA, Vaillancourt JP, Diang CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebuik YA, Munday NA, Raju SM, Smulson ME, Yamin TT, Yu VL and Miller DK (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature (London) 376: 37-43.
27. Nitiss JL and Beck WT (1996) Antitopoisomerase drug action and resistance. Eur J Cancer 42A:958-966.
28. Roca J, Ishida R, Berger JM, Andoh T and Wang JC (1994) Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 91:1781-1785.
29. 2-terminal kinase-mediated activation of Interleukin-1β Converting Enzyme/CED-3-like protease during anticancer drug-induced apoptosis. J Biol Chem 272:4631-4636.
30. Tamura T, Ishihara M, Lamphier MS, Tanaka N, Oishi I, Aizawa S, Matsuyama T, Mak T, Taki S and Taniguchi T (1995) An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature (London)376:596-599.
31. Tanabe K, Ikegami Y, Ishida R and Andoh T (1991) Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 51:4903-4908.
32. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng, Z, Beidler DR, Poirer GG, Salvesen GS and Dixit VM (1995) Yama/CPP32β, a mammalian homolog for CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81:801-809.
33. Thornberry NA (1997) The caspase family of cysteine proteases. Br Med Bull 53: 478-490.
34. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR and Aunins J (1992) A novel heterodimeric cysteine protease is required for interleukin-1-beta processing in monocytes. Nature (London) 356:768-774.
35. Thornberry NA and Molineaux SM (1995) Interleukin-1β converting enzyme: A novel cystein protease required for IL-1β production and implicated in programmed cell death. Protein Sci 4:3-12.
36. Wang Z-Q, Stingl L, Morrison C, Jantsch M, Los M, Schulze-Osthoff K and Wagner EF (1997) PARP is important for genomic stability but dispensable in apoptosis. Genes & Dev 11:2347-2358.
37. White E (1996) Life, death and the pursuit of apoptosis. Genes & Dev 10:1-15.
38. Wyllie AH (1997) Apoptosis: An overview. Br Med Bull 53:451-465.
39. Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:1326-1331.
40. Zanke BW, Boudreau K, Rubie E, Winnett E, Tibbles LA, Zon L, Kyriakis J, Liu F-F and Woodgett JR (1996) The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat. Curr Biol 6:606-613.